A5064933173- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Cancer-related molecular mechanisms research
- Synthesis and Catalytic Reactions
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Meningioma and schwannoma management
- Computational Drug Discovery Methods
- Asymmetric Hydrogenation and Catalysis
- Lung Cancer Research Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Immune Cell Function and Interaction
- Immune cells in cancer
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Mycobacterium research and diagnosis
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
- Epigenetics and DNA Methylation
- T-cell and B-cell Immunology
- Pituitary Gland Disorders and Treatments
- Single-cell and spatial transcriptomics
- Head and Neck Surgical Oncology
Brigham and Women's Hospital
2016-2025
Harvard University
2016-2025
Dana-Farber Cancer Institute
2018-2025
Broad Institute
2020-2025
The University of Texas MD Anderson Cancer Center
2022-2025
Central Brain Tumor Registry of the United States
2022
Center for Neuro-Oncology
2021
Massachusetts Institute of Technology
2020
University of California, San Francisco
2014-2018
University of Louisville
2018
Decompression surgery followed by adjuvant radiotherapy is an effective therapy for preservation or recovery of neurological function and achieving durable local disease control in patients suffering from metastatic epidural spinal cord compression (ESCC). The authors examine the outcomes postoperative image-guided intensity-modulated radiation delivered as single-fraction hypofractionated stereotactic radiosurgery (SRS) long-term tumor control.A retrospective chart review identified 186...
Abstract Recent technological innovations have enabled the high-throughput quantification of gene expression and epigenetic regulation within individual cells, transforming our understanding how complex tissues are constructed 1–6 . However, missing from these measurements is ability to routinely easily spatially localize profiled cells. We developed a strategy, Slide-tags, in which single nuclei an intact tissue section tagged with spatial barcode oligonucleotides derived DNA-barcoded beads...
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1–6. However, whether such target driver mutations, lead to recognition of a patient's tumour and result in clinical activity are largely unknown. These questions particular interest for patients who have tumours with low mutational burden. Here we conducted phase I trial (ClinicalTrials.gov identifier NCT02950766) test neoantigen-targeting PCV high-risk, fully resected clear cell renal...
Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from body-thereby, allowing more be sampled-has been proposed improve performance liquid biopsy diagnostics. However, there paucity clinical data on effect higher recovery. Here, we investigated impact collecting greater quantities...
Atypical (WHO Grade II) meningiomas comprise a heterogeneous group of tumors, with histopathology delineated under the guidance WHO and spectrum clinical outcomes. The role postoperative radiotherapy for patients atypical who have undergone gross-total resection (GTR) remains unclear. In this paper, authors sought to clarify by reviewing their experience over past 2 decades.The retrospectively analyzed all at institution underwent GTR between 1992 2011 final histology demonstrating...
Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors decrease tumor-associated edema, but limited data exist describing how dexamethasone affects the immune system systemically and intratumorally in glioblastoma (GBM), particularly context of immunotherapy.We evaluated dose-dependent effects when programmed cell death 1 (PD-1) blockade and/or radiotherapy immunocompetent C57BL/6 mice syngeneic GL261 CT-2A GBM tumors. Clinically, effect on...
High-grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO4929097 has emerged as potential therapeutic option based on modulation of cancer-initiating cell (CIS) population and presumed antiangiogenic role.In this phase 0/I trial, 21 patients newly diagnosed glioblastoma or anaplastic astrocytoma received combined temozolomide radiotherapy. In addition to establishing MTD, study design enabled exploratory studies evaluating tumor brain...
Computer 3D navigation (3D NAV) techniques in spinal instrumentation can theoretically improve screw placement accuracy and reduce injury to critical neurovascular structures, especially complex cases. In this series, we analyze the results of NAV pedicle accuracy, outer diameter, case complexity comparison with screws placed conventional lateral fluoroscopy.Pedicle cervical, thoracic, or lumbar spine using either standard fluoroscopy isocentric were retrospectively analyzed. The each...
Molecularly-defined diffuse glioma types-including IDH-wildtype glioblastoma, IDH-mutant astrocytoma, 1p/19q-codeleted oligodendroglioma, and H3 K27M-mutant midline glioma-were incorporated into U.S. cancer registry reporting for individuals with brain tumors beginning in 2018. We leveraged these new data to estimate the national-level overall survival (OS) patterns associated integrated diagnoses.
Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated completeness and validity of these variables described epidemiology molecularly defined tumor types.
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, CD8 + T cell blocking studies mice, demonstrated this results from an inflammatory response following antiprogrammed death 1 (PD1) antibody treatment disrupts the blood–tumor barrier. Used lieu of immunosuppressive corticosteroids, angiotensin receptor blocker...
PURPOSE Microsatellite instability (MSI) and DNA mismatch repair (MMR) status is an indispensable biomarker in the management of colorectal cancers. We therefore examined epidemiology MSI-high/MMR-deficient cancers United States. METHODS Adults presenting with adenocarcinoma 2018-2019 were identified from US National Cancer Database. Attributes associated MSI-high/MMR-deficiency using multivariable logistic regression reported average adjusted probabilities (% AAP ) 99.9% CIs. As a secondary...
mAbs targeting the PD-1/PD-L1 immune checkpoint are powerful tools to improve survival of patients with cancer. Understanding molecular basis clinical response these treatments is critical identify who can benefit from this immunotherapy. In study, we investigated long noncoding RNA (lncRNA) expression in cancer treated anti-PD-1/PD-L1 immunotherapy.lncRNA profile was analyzed one cohort melanoma and two independent cohorts glioblastoma (GBM) undergoing Single-cell RNA-sequencing analyses...
Abstract Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop TKI resistance by secondary mutations alterative oncogenes, of which oncogenes pose a greater challenge for disease management because multiple potential mechanisms and the unclear tolerability drug combinations. A patient metastatic medullary thyroid carcinoma (MTC) harboring activation loop D898_E901del mutation was selpercatinib. Molecular alterations were monitored tissue...
Abstract Introduction This study aimed to assess the feasibility of implementing Idylla system, an ultra‐rapid, cartridge‐based assay, as extension rapid on‐site evaluation (ROSE) in cytology. The authors conducted a pilot validation on specimens from non–small cell lung carcinoma, thyroid and melanoma, evaluating four assays designed detect alterations KRAS , EGFR BRAF gene fusions, expression imbalances ALK ROS1 RET NTRK 1/2/3, MET exon 14 skipping transcripts. They investigated providing...